Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 95Thoracic 23Breast 17Head & Neck 15Dermatologic 13Sarcoma 11Gynecologic 10Genitourinary 9CNS 7Other hematologic neoplasm 2NET 2Endocrine 2Classical hematology 2

Conditions

Neuroendocrine Tumors 69Pheochromocytoma 8Gastro-enteropancreatic neuroendocrine tumor 8Carcinoma, Neuroendocrine 8Paraganglioma 7Carcinoid Tumor 7Adenoma, Islet Cell 7Sarcoma 6Thyroid Neoplasms 5Pancreatic Neoplasms 5Neoplasms 5Melanoma 5Breast Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Neuroblastoma 4Neoplasm Metastasis 4Mesothelioma 4Carcinoma, Merkel Cell 4Carcinoma 4Stomach Neoplasms 3Neuroectodermal Tumors, Primitive 3Meningioma 3Liver Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Central Nervous System Neoplasms 3Carcinoma, Non-Small-Cell Lung 3

Interventions

repotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × NET × 90 days × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06263088 2026-05-22

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

Case Comprehensive Cancer Center

Phase NA Recruiting
200 enrolled
EndocrineGastrointestinalNET

Anus Neoplasms, Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡